NDAORALTABLET
Approved
Jan 1961
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
6/8 — Strong
ALDACTAZIDE (spironolactone and hydrochlorothiazide) by Pfizer is aldosterone antagonists [moa]. Approved for thiazide diuretic [epc], hypertension, to lower blood pressure and 15 more indications. First approved in 1961.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ALDACTAZIDE is an oral combination tablet of spironolactone (aldosterone antagonist) and hydrochlorothiazide (thiazide diuretic) approved by FDA in 1961. It is indicated for hypertension management and treatment of diuretic-induced hypokalemia in congestive heart failure patients. The dual mechanism reduces blood pressure through aldosterone antagonism and enhanced sodium-chloride excretion.
$32KPart D
LOE ApproachingDeclining
This 60+ year-old product faces patent expiration with minimal current spending ($32K in Part D claims) and declining market relevance, indicating small team size and focus on managed care maintenance.
Mechanism of Action
Aldosterone Antagonists
Pharmacologic Class:
Thiazide Diuretic
Indications (17)
Worked on ALDACTAZIDE at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.